| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | hly9; mLY9; CD229; SLAMF3 |
| Entrez GeneID | 4063 |
| WB Predicted band size | Calculated MW: 72 kDa; Observed MW: 72 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Recombinant protein of human CD229 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于CD229(Ly9)抗体的3篇代表性文献，按领域和内容分类简要整理：
---
1. **文献名称**：*Structural basis of CD229/Ly9 signaling in immune regulation*
**作者**：Smith A, et al.
**摘要**：该研究解析了CD229分子的晶体结构，揭示其胞外域与特异性抗体结合的位点，并探讨CD229在T细胞活化中的调控机制，为开发靶向CD229的免疫疗法提供结构基础。
---
2. **文献名称**：*CD229/Ly9 deficiency alters B cell tolerance checkpoints and promotes autoimmunity*
**作者**：González-Bueno CV, et al.
**摘要**：通过CD229基因敲除小鼠模型，研究发现CD229抗体可阻断其与配体SLAMF6的相互作用，导致B细胞耐受失调，提示CD229在自身免疫疾病(如红斑狼疮)中的潜在治疗价值。
---
3. **文献名称**：*Targeting CD229 with CAR-T cells shows preclinical efficacy in multiple myeloma*
**作者**：Wang Y, et al.
**摘要**：该研究开发了靶向CD229的CAR-T细胞，在体外和多发性骨髓瘤小鼠模型中验证其抗肿瘤活性，表明CD229抗体在肿瘤免疫治疗中的应用潜力。
---
**备注**：以上文献为示例，实际文献需通过PubMed/Google Scholar检索。若需具体文献年份或DOI，建议补充关键词(如“CD229 antibody cancer”或“CD229 structure”)进一步筛选。
CD229. also known as Ly9. is a cell surface glycoprotein belonging to the Signaling Lymphocyte Activation Molecule (SLAM) family. Primarily expressed on T cells, B cells, and natural killer (NK) cells, it plays a role in modulating immune cell activation, adhesion, and differentiation. Structurally, CD229 contains four immunoglobulin-like domains in its extracellular region and cytoplasmic tyrosine-based signaling motifs that recruit adaptor proteins like SAP (SLAM-associated protein), facilitating downstream signaling pathways.
CD229 antibodies are tools used to study its function in immune regulation and disease. Research indicates that CD229 is involved in autoimmune disorders and cancers, with altered expression observed in conditions like systemic lupus erythematosus (SLE) and multiple myeloma. In cancer, CD229 antibodies have been explored for therapeutic potential, particularly in targeting plasma cell malignancies, where CD229 is highly expressed. These antibodies may enable targeted drug delivery or stimulate immune responses against malignant cells.
Additionally, CD229 antibodies serve as biomarkers for lymphocyte subset analysis in flow cytometry, aiding in immunophenotyping. Recent studies also investigate their role in modulating immune checkpoints, as CD229 interacts with pathways that balance immune activation and tolerance. While therapeutic applications remain experimental, CD229's unique expression profile and signaling functions make it a promising target for immunotherapy and diagnostic development. Ongoing research aims to clarify its precise mechanisms and optimize antibody-based interventions.
×
